{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:57:00Z","timestamp":1773129420771,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2320-4","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"187-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Discontinuation of tyrosine kinase therapy in CML"],"prefix":"10.1007","volume":"94","author":[{"given":"Francois-Xavier","family":"Mahon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"2320_CR1","unstructured":"National Comprehensive Cancer Network (2012) Chronic Myelogenous Leukemia. NCCN Clinical Practice Guidelines in Oncology; v1.2013"},{"key":"2320_CR2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"2320_CR3","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11899-012-0117-2","volume":"7","author":"D Rea","year":"2012","unstructured":"Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX (2012) Curing chronic myeloid leukemia. Curr Hematol Malig Rep 7:103\u2013108","journal-title":"Curr Hematol Malig Rep"},{"key":"2320_CR4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58\u201360","journal-title":"Blood"},{"key":"2320_CR5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/asheducation.V2012.1.122.3798214","volume":"2012","author":"FX Mahon","year":"2012","unstructured":"Mahon FX (2012) Is going for cure in chronic myeloid leukemia possible and justifiable? Hematol Am Soc Hematol Educ Program 2012:122\u2013128","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2320_CR6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029\u20131035","journal-title":"Lancet Oncol"},{"key":"2320_CR7","unstructured":"Mahon F, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE et al (2013) Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM Study. Blood (ASH Annual Meeting Abstracts);122, [abstract 255]"},{"key":"2320_CR8","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"24","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719\u20131724","journal-title":"Leukemia"},{"key":"2320_CR9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Arthur C, Schwarer AP, Dang P et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515\u2013522","journal-title":"Blood"},{"key":"2320_CR10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","volume":"97","author":"N Takahashi","year":"2012","unstructured":"Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T et al (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97:903\u2013906","journal-title":"Haematologica"},{"key":"2320_CR11","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204\u20132205","journal-title":"Blood"},{"issue":"S1","key":"2320_CR12","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.leukres.2003.10.017","volume":"28","author":"MJ Mauro","year":"2004","unstructured":"Mauro MJ, Druker BJ, Marziaz RT (2004) Divergent clinical outcome in twp CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28(S1):S71\u2013S73","journal-title":"Leuk Res"},{"key":"2320_CR13","first-page":"979","volume":"90","author":"S Merante","year":"2005","unstructured":"Merante S, Orlandi E, Bernasconi P et al (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979\u2013981","journal-title":"Haematologica"},{"key":"2320_CR14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267\u20131270","journal-title":"Nature"},{"key":"2320_CR15","doi-asserted-by":"crossref","unstructured":"Mahon FX, Nicolini F, No\u00ebl MP, Escoffre M, Charbonnier A, Rea D, Dubruille V, Varet B, Legros L, Guerci A, Etienne G, Guilhot F, Dulucq S, Rousselot P, Guilhot J (2013) Preliminary Report Of The STIM2 Study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood (ASH Annual Meeting Abstracts) [abstract 654]","DOI":"10.1182\/blood.V122.21.654.654"},{"key":"2320_CR16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424\u2013430","journal-title":"J Clin Oncol"},{"issue":"supl. 1","key":"2320_CR17","first-page":"LB-6214","volume":"99","author":"S Saussele","year":"2014","unstructured":"Saussele S, Richter J, Guilhot J, M\u00fcller MC, Dietz C, Porkka K et al (2014) First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. 19th Congress of the European Hematology Association, Milan, Italy, June 12\u201315, 2014. Haematologica 99(supl. 1):LB-6214","journal-title":"Haematologica"},{"key":"2320_CR18","doi-asserted-by":"crossref","unstructured":"Mahon FX, Baccarani M, Mauro M et al (2014) Treatment-free remission following nilotinib in patients with chronic myeloid leukemia in chronic phase: ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath ASCO meeting 2014. J Clin Oncol 32:5s, (suppl; abstr TPS7124)","DOI":"10.1200\/jco.2014.32.15_suppl.tps7124"},{"key":"2320_CR19","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","volume":"21","author":"AM Stein","year":"2011","unstructured":"Stein AM, Bottino D, Modur V et al (2011) BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 21:6812\u20136821","journal-title":"Clin Cancer Res"},{"key":"2320_CR20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","volume":"121","author":"M Horn","year":"2013","unstructured":"Horn M, Glauche I, M\u00fcller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I (2013) Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 121:378\u2013384","journal-title":"Blood"},{"issue":"10","key":"2320_CR21","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","volume":"26","author":"NCP Cross","year":"2012","unstructured":"Cross NCP, White H, M\u00fcller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172\u20132175","journal-title":"Leukemia"},{"key":"2320_CR22","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"S Branford","year":"2007","unstructured":"Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al (2007) BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 13:7080\u20137085","journal-title":"Clin Cancer Res"},{"key":"2320_CR23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/asheducation-2011.1.136","volume":"2011","author":"JV Melo","year":"2011","unstructured":"Melo JV, Ross DM (2011) Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematol Am Soc Hematol Educ Program 2011:136\u2013142","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2320_CR24","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","volume":"8","author":"C Biernaux","year":"1995","unstructured":"Biernaux C, Loos M, Sels A et al (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 8:3118\u20133122","journal-title":"Blood"},{"key":"2320_CR25","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","volume":"92","author":"S Bose","year":"1998","unstructured":"Bose S, Deininger M, Gora-Tybor J et al (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362\u20133367","journal-title":"Blood"},{"key":"2320_CR26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrclinonc.2011.17","volume":"3","author":"M Deininger","year":"2011","unstructured":"Deininger M (2011) Hematology: curing CML with imatinib\u2014a dream come true? Nat Rev Clin Oncol 3:127\u2013128","journal-title":"Nat Rev Clin Oncol"},{"key":"2320_CR27","doi-asserted-by":"crossref","unstructured":"R\u00e9a D, Rousselot P, Nicolini F, Legros L, Tulliez M, Giraudier S, Cony-Makhoul P, Guilhot F, Mahon FX (2011) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia patients with stable undetectable BCR-ABL transcripts: results from the French CML group (FI-LMC) Blood (ASH) 2012: Abstract 9168. Rea D, et al. Blood.;118(21) [abstract 604]","DOI":"10.1182\/blood.V118.21.604.604"},{"key":"2320_CR28","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.leukres.2012.02.011","volume":"36","author":"HY Yhim","year":"2012","unstructured":"Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S et al (2012) Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 36:689\u2013693","journal-title":"Leuk Res"},{"key":"2320_CR29","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","volume":"121","author":"S Branford","year":"2013","unstructured":"Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818\u20133824","journal-title":"Blood"},{"key":"2320_CR30","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/ajh.23560","volume":"88","author":"L Falchi","year":"2013","unstructured":"Falchi L, Kantarjian HM, Wang X et al (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88:1024\u20131029","journal-title":"Am J Hematol"},{"key":"2320_CR31","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423","journal-title":"J Clin Oncol"},{"key":"2320_CR32","unstructured":"Rea D, Dulphy N, Henry G, J Guilhot J, Guilhot F, Franck E. Nicolini, Legros L, Rousselot Ph, Mahon FX, Toubert A (2013) Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM investigators. Blood (ASH Annual Meeting Abstracts); 122 (suppl): [abstract 856)"},{"key":"2320_CR33","doi-asserted-by":"crossref","unstructured":"Ilander MM, Olsson-Str\u00f6mberg U, L\u00e4hteenm\u00e4ki H et al (2013) Disease Relapse After TKI Discontinuation in CML is related both To low number and impaired function of NK-cells: data from Euro-SKI. Blood (ASH Annual Meeting Abstracts); 122 (suppl): [abstract 379)","DOI":"10.1182\/blood.V122.21.379.379"},{"key":"2320_CR34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1200\/JCO.20.1.214","volume":"20","author":"FX Mahon","year":"2002","unstructured":"Mahon FX, Delbrel X, Cony-Makhoul P et al (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214\u2013220","journal-title":"J Clin Oncol"},{"key":"2320_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1\u20137","journal-title":"Leuk Lymphoma"},{"key":"2320_CR36","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.hoc.2011.09.001","volume":"25","author":"P Gallipoli","year":"2011","unstructured":"Gallipoli P, Abraham SA, Holyoake TL (2011) Hurdles toward a cure for CML: the CML stem cell. Hematol Oncol Clin N Am 25:951\u2013966","journal-title":"Hematol Oncol Clin N Am"},{"key":"2320_CR37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11899-012-0117-2","volume":"7","author":"D Rea","year":"2012","unstructured":"Rea D, Rousselot P, Guilhot J et al (2012) Curing chronic myeloidleukemia. Curr Hematol Malignancy Rep 7:103\u2013108","journal-title":"Curr Hematol Malignancy Rep"},{"key":"2320_CR38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","volume":"8","author":"O Hantschel","year":"2012","unstructured":"Hantschel O, Warsch W, Eckelhart E et al (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8:285\u2013293","journal-title":"Nat Chem Biol"},{"key":"2320_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/187152010790909326","volume":"10","author":"Y Chen","year":"2010","unstructured":"Chen Y, Peng C, Sullivan C et al (2010) Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anti Cancer Agents Med Chem 10:111\u2013115","journal-title":"Anti Cancer Agents Med Chem"},{"key":"2320_CR40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","volume":"17","author":"B Zhang","year":"2010","unstructured":"Zhang B, Strauss AC, Chu S et al (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17:427\u2013442","journal-title":"Cancer Cell"},{"key":"2320_CR41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","volume":"21","author":"L Li","year":"2012","unstructured":"Li L, Wang L, Li L et al (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21:266\u2013281","journal-title":"Cancer Cell"},{"key":"2320_CR42","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","volume":"208","author":"C Hurtz","year":"2011","unstructured":"Hurtz C, Hatzi K, Cerchietti L et al (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208:2163\u20132174","journal-title":"J Exp Med"},{"key":"2320_CR43","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.stem.2012.03.006","volume":"10","author":"M Kleppe","year":"2012","unstructured":"Kleppe M, Levine RL (2012) Targeting beta-catenin in CML: leukemiastem cells beware! Cell Stem Cell 10:351\u2013353","journal-title":"Cell Stem Cell"},{"key":"2320_CR44","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","volume":"14","author":"C Dierks","year":"2008","unstructured":"Dierks C, Beigi R, Guo GR et al (2008) Expansion of Bcr-Ablpositive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14:238\u2013249","journal-title":"Cancer Cell"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2320-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2320-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2320-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T05:24:03Z","timestamp":1598851443000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2320-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":44,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2320"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2320-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}